Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 7NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

fludarabine phosphate 2fludarabine 2Whole-Body Irradiation 2Tacrolimus 2Surveys and Questionnaires 2Proton Therapy 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Music Therapy 2Mesna 2Melphalan 2Interviews as Topic 2Gene Expression Profiling 2Cyclophosphamide 2Busulfan 2tremelimumab 1motesanib diphosphate 1luprolide acetate gel depot 1liposomal amphotericin B 1durvalumab 1copanlisib 1chlorhexidine gluconate 1batifiban 1Whole Genome Sequencing 1Watchful Waiting 1Thrombopoietin 1Taxes 1Spermine Synthase 1Radiotherapy, Intensity-Modulated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Neoplasms × Olanzapine × Clear all
NCT02400866 2015-03-27

A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy

Korean South West Oncology Group

Phase 2 Unknown
58 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡